Sign in
CompletedPhase 2

Assessment of the Clinical, Cellular and Molecular Effects of Royalactin-Royal Jelly on the Healing of Wagner Grad II Diabetic Foot Ulcers.

Key facts

Who runs it
Universidad Autonoma de Nuevo Leon
Where
Mexico1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
10 people enrolled
Started
9 Sept 2022
Ended
30 Oct 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Royalactina
  • Placebo
Record updated
3 April 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Confirmed diagnosis of Diabetes Mellitus according to the 2020 ADA guidelines
  • Stage II ulcer according to the Wagner classification for Diabetic Foot (deep ulcer, penetrating ligaments and muscles, without bone involvement or abscess formation)
  • Ulcer located on any area of the foot or ankle
  • Ulcer with 80% granulation tissue
  • Ankle-brachial index greater than 0.5 (not considered severe or critical arterial disease)
  • Negative stylet test
  • Ability to attend wound care and follow-up appointments three times a week for four weeks
  • Signed informed consent form

Who cannot take part

  • History of hypersensitivity reactions to dermatological products
  • History of generalized dermatological pathology or pathology affecting the foot
  • Diagnosis of autoimmune disease
  • Local or systemic infection
  • Hypersensitivity to any of the components of the experimental product

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to evaluate the clinical, cellular, and molecular effects of Royalactin as an adjunct to standard treatment, compared to standard treatment alone, in the treatment of Wagner grade II diabetic foot ulcers by assessing wound size, cell behavior (Epithelialization, polymorphonuclear neutrophils, fibroblasts, angiogenesis, and collagen), and growth factor expression. This is a prospective, randomized, double-blind, double-blind, experimental, longitudinal, comparative, controlled clinical trial.

The 2 groups in the trial

  • Diabetic foot ulcers treated with RoyalactinExisting treatment, for comparison

    Standardized wound care is performed 3 times a week with the application of Royalactin.

    Treatment: Royalactina

  • Diabetic foot ulcers with placebo applicationPlacebo, for comparison

    Standardized treatments are performed 3 times a week with placebo application.

    Treatment: Placebo

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
3 April 2026